Connection
Matthew Ellis to Retreatment
This is a "connection" page, showing publications Matthew Ellis has written about Retreatment.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.115 |
|
|
|
-
Ben-Baruch NE, Bose R, Kavuri SM, Ma CX, Ellis MJ. HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor. J Natl Compr Canc Netw. 2015 Sep; 13(9):1061-4.
Score: 0.115